Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AAPGNASDAQ:HUMANASDAQ:IDYANASDAQ:SDGR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$18.46-2.7%$0.00$16.50▼$21.40$1.65BN/A89,214 shs15,886 shsHUMAHumacyte$2.88-13.3%$3.76$2.75▼$9.97$362.47M1.363.16 million shs4.63 million shsIDYAIDEAYA Biosciences$18.01-3.1%$21.12$16.95▼$44.42$1.58B0.76823,155 shs937,174 shsSDGRSchrödinger$21.45-5.7%$23.03$16.67▼$29.15$1.57B1.62746,764 shs848,533 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International-2.69%-6.25%-12.80%+1,845,999,900.00%+1,845,999,900.00%HUMAHumacyte-13.25%-7.99%-18.76%-36.14%-8.28%IDYAIDEAYA Biosciences-3.12%-2.49%-17.20%-28.81%-57.43%SDGRSchrödinger-5.71%-6.33%-5.26%+8.72%-15.92%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/AN/AN/AN/AHUMAHumacyte2.0969 of 5 stars3.51.00.00.02.61.70.6IDYAIDEAYA Biosciences3.52 of 5 stars3.50.00.04.43.11.70.0SDGRSchrödinger2.7366 of 5 stars3.52.00.00.03.02.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAPGAscentage Pharma Group International 0.00N/AN/AN/AHUMAHumacyte 3.00Buy$13.71376.19% UpsideIDYAIDEAYA Biosciences 2.93Moderate Buy$53.58197.52% UpsideSDGRSchrödinger 3.00Buy$32.2950.52% UpsideCurrent Analyst Ratings BreakdownLatest HUMA, SDGR, AAPG, and IDYA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/12/2025HUMAHumacyteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/7/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.002/27/2025HUMAHumacyteBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy2/27/2025SDGRSchrödingerPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$50.00 ➝ $45.002/26/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.002/14/2025IDYAIDEAYA BiosciencesStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$50.00 ➝ $50.001/24/2025SDGRSchrödingerKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$25.00 ➝ $27.001/21/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.001/15/2025IDYAIDEAYA BiosciencesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$61.00 ➝ $61.001/13/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.001/13/2025IDYAIDEAYA BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight(Data available from 3/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAPGAscentage Pharma Group International$903.03M1.78N/AN/AN/A∞HUMAHumacyte$1.57M230.88N/AN/A$0.13 per share22.15IDYAIDEAYA Biosciences$7M225.22N/AN/A$12.10 per share1.49SDGRSchrödinger$207.54M7.55$0.57 per share37.42$7.60 per share2.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAPGAscentage Pharma Group InternationalN/AN/A0.00∞N/AN/AN/AN/AN/AHUMAHumacyte-$110.78M-$1.34N/AN/AN/AN/A-942.81%-93.82%3/28/2025 (Estimated)IDYAIDEAYA Biosciences-$274.48M-$3.30N/AN/AN/AN/A-26.74%-25.54%5/6/2025 (Estimated)SDGRSchrödinger$40.72M-$2.57N/AN/AN/A-91.84%-35.77%-24.51%4/29/2025 (Estimated)Latest HUMA, SDGR, AAPG, and IDYA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2025N/AHUMAHumacyte-$0.24N/AN/AN/AN/AN/A2/26/2025Q4 2024SDGRSchrödinger-$0.35-$0.55-$0.20-$0.55$83.20 million$88.32 million2/13/2025Q4 2024IDYAIDEAYA Biosciences-$0.67-$1.49-$0.82-$1.49$7.00 million$7.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/AHUMAHumacyteN/AN/AN/AN/AN/AIDYAIDEAYA BiosciencesN/AN/AN/AN/AN/ASDGRSchrödingerN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAPGAscentage Pharma Group InternationalN/AN/AN/AHUMAHumacyteN/A1.101.10IDYAIDEAYA BiosciencesN/A14.9722.93SDGRSchrödingerN/A4.114.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAPGAscentage Pharma Group InternationalN/AHUMAHumacyte44.71%IDYAIDEAYA Biosciences98.29%SDGRSchrödinger79.05%Insider OwnershipCompanyInsider OwnershipAAPGAscentage Pharma Group InternationalN/AHUMAHumacyte11.20%IDYAIDEAYA Biosciences3.50%SDGRSchrödinger8.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAPGAscentage Pharma Group International60087.07 millionN/AN/AHUMAHumacyte150125.86 million111.76 millionOptionableIDYAIDEAYA Biosciences8087.54 million84.47 millionOptionableSDGRSchrödinger79073.04 million66.59 millionOptionableHUMA, SDGR, AAPG, and IDYA HeadlinesRecent News About These CompaniesSchrödinger to Present Preclinical Data at AACR Annual MeetingMarch 25 at 9:01 PM | finance.yahoo.comSchrödinger, Inc. (NASDAQ:SDGR) Position Boosted by AmundiMarch 21, 2025 | marketbeat.comSchrödinger (NASDAQ:SDGR) Shares Down 5.4% - What's Next?March 19, 2025 | marketbeat.comTejara Capital Ltd Trims Stake in Schrödinger, Inc. (NASDAQ:SDGR)March 19, 2025 | marketbeat.comNikko Asset Management Americas Inc. Boosts Stock Position in Schrödinger, Inc. (NASDAQ:SDGR)March 18, 2025 | marketbeat.comBank of New York Mellon Corp Sells 27,211 Shares of Schrödinger, Inc. (NASDAQ:SDGR)March 16, 2025 | marketbeat.com80,000 Shares in Schrödinger, Inc. (NASDAQ:SDGR) Acquired by Monaco Asset Management SAMMarch 15, 2025 | marketbeat.comSchrödinger (NASDAQ:SDGR) Trading Up 11.3% - Should You Buy?March 12, 2025 | marketbeat.comSchrödinger beruft Bridget van Kralingen in den VorstandMarch 10, 2025 | de.investing.comSchrödinger Expands Board of Directors with Appointment of Bridget van KralingenMarch 10, 2025 | finance.yahoo.comSchrödinger Expands Board of Directors with Appointment of Bridget van KralingenMarch 10, 2025 | businesswire.comInsider Selling: Schrödinger, Inc. (NASDAQ:SDGR) CFO Sells 5,491 Shares of StockMarch 5, 2025 | marketbeat.comLeerink Partnrs Estimates Schrödinger FY2029 EarningsMarch 3, 2025 | marketbeat.comSchrödinger, Inc. (NASDAQ:SDGR) Receives Average Recommendation of "Buy" from BrokeragesMarch 2, 2025 | marketbeat.comSchrödinger: Still Waiting On A CatalystMarch 2, 2025 | seekingalpha.comSchrödinger, Inc. (SDGR) Q4 2024 Earnings Call TranscriptMarch 1, 2025 | seekingalpha.comSchrödinger, Inc. (SDGR) Q4 2024 Earnings Call TranscriptMarch 1, 2025 | seekingalpha.comSchrödinger (NASDAQ:SDGR) Trading Up 7.7% - Here's What HappenedFebruary 28, 2025 | marketbeat.comPiper Sandler Lowers Schrödinger (NASDAQ:SDGR) Price Target to $45.00February 28, 2025 | marketbeat.comSchrodinger price target lowered to $45 from $50 at Piper SandlerFebruary 27, 2025 | markets.businessinsider.comSchrödinger (NASDAQ:SDGR) Releases Quarterly Earnings Results, Misses Estimates By $0.20 EPSFebruary 27, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHUMA, SDGR, AAPG, and IDYA Company DescriptionsAscentage Pharma Group International NASDAQ:AAPG$18.46 -0.51 (-2.69%) As of 03/25/2025 04:00 PM EasternAscentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.Humacyte NASDAQ:HUMA$2.88 -0.44 (-13.25%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$2.33 -0.56 (-19.27%) As of 03/25/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.IDEAYA Biosciences NASDAQ:IDYA$18.01 -0.58 (-3.12%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$18.01 0.00 (0.00%) As of 03/25/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Schrödinger NASDAQ:SDGR$21.45 -1.30 (-5.71%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$21.58 +0.13 (+0.58%) As of 03/25/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Insiders Sell: This Is What It Means for the Market Oklo’s Stock Price Meltdown Is an Opportunity to Buy Top Dividend Stocks With Over 10 Years of Hikes—and Room to Grow Quantum Gamble? Is IonQ's Stock an Opportunity or a Mirage? Will CrowdStrike's FedRAMP Authorization Move CRWD Stock? Top 3 Insider Stock Buys in March—Are They Still Good in April? Taiwan Semiconductor Attracts Big Money on NVIDIA Chip Growth D-Wave Stock: Is Quantum Blockchain the Next Big Catalyst? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
